Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Tallantyre

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Multiple Sclerosis and Related Disorders|March 13, 2024
Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorderMoneeb Nasir, Luke Hone, Emma Tallantyre, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 15, 2015
Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesionsNiraj Mistry, Rasha Abdel-Fahim, Amal Samaraweera, et al.
International Journal of MS Care|July 9, 2024
The Impact of COVID-19 on the Employment of People With Multiple Sclerosis: A Multiple Methods StudyBlanca De Dios Perez, Charlotte Pritchard, Katie Powers, et al.
JAMA Neurology|February 19, 2019
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple SclerosisKatharine Harding, Owain Williams, Mark Willis, et al.
European Journal of Neurology|June 10, 2026
Defining Activity-Based Subgroups in Multiple Sclerosis: A Review and Framework ProposalCatalina Lopez Manzano, Claire M Rice, Emma Tallantyre, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 20, 2017
An observational study of alemtuzumab following fingolimod for multiple sclerosisMark Willis, Owen Pearson, Zsolt Illes, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 19, 2023
Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort studyAthanasios Papathanasiou, Aimee Hibbert, Emma Tallantyre, et al.
European Journal of Neurology|February 9, 2026
MOGAD in South Wales: Diagnostic Evolution and Disease EpidemiologySophie Voase, Patrick Waters, Stephen Jolles, et al.
BMJ Open|March 17, 2021
Web-based physical activity intervention for people with progressive multiple sclerosis: application of consensus-based intervention development guidanceMonica Busse, Julie Latchem-Hastings, Kate Button, et al.
Brain Pathology (Zurich, Switzerland)|March 6, 2025
Sterol imbalances and cholesterol-24-hydroxylase dysregulation is linked to the underlying progression of multiple sclerosisLauren Griffiths, Kristen Hawkins, Eylan Yutuc, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Multiple Sclerosis and Related Disorders|March 13, 2024
Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorderMoneeb Nasir, Luke Hone, Emma Tallantyre, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 15, 2015
Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesionsNiraj Mistry, Rasha Abdel-Fahim, Amal Samaraweera, et al.
International Journal of MS Care|July 9, 2024
The Impact of COVID-19 on the Employment of People With Multiple Sclerosis: A Multiple Methods StudyBlanca De Dios Perez, Charlotte Pritchard, Katie Powers, et al.
JAMA Neurology|February 19, 2019
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple SclerosisKatharine Harding, Owain Williams, Mark Willis, et al.
European Journal of Neurology|June 10, 2026
Defining Activity-Based Subgroups in Multiple Sclerosis: A Review and Framework ProposalCatalina Lopez Manzano, Claire M Rice, Emma Tallantyre, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 20, 2017
An observational study of alemtuzumab following fingolimod for multiple sclerosisMark Willis, Owen Pearson, Zsolt Illes, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 19, 2023
Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort studyAthanasios Papathanasiou, Aimee Hibbert, Emma Tallantyre, et al.
European Journal of Neurology|February 9, 2026
MOGAD in South Wales: Diagnostic Evolution and Disease EpidemiologySophie Voase, Patrick Waters, Stephen Jolles, et al.
BMJ Open|March 17, 2021
Web-based physical activity intervention for people with progressive multiple sclerosis: application of consensus-based intervention development guidanceMonica Busse, Julie Latchem-Hastings, Kate Button, et al.
Brain Pathology (Zurich, Switzerland)|March 6, 2025
Sterol imbalances and cholesterol-24-hydroxylase dysregulation is linked to the underlying progression of multiple sclerosisLauren Griffiths, Kristen Hawkins, Eylan Yutuc, et al.
Pageof 3